Cantor Fitzgerald upgraded UniQure NV (NASDAQ: QURE) to "Overweight" with a new price target of $80.UniQure's stock surged 248% after successful trial results for its Huntington's disease gene therapy.Analysts from Stifel, Leerink, and Mizuho have significantly raised their price targets for QURE, indicating strong confidence in its future performance.UniQure NV (NASDAQ: QURE) is a biotechnology company focused on developing gene therapies. It aims to provide innovative treatments for patients with severe g ...